Majid Al Futtaim and Authentic Brands Group Sign Partnership to Expand Juicy Couture across MENA

Agreement makes Majid Al Futtaim Fashion the master distributor for the brand throughout the Middle East

HONG KONG, Jan. 23, 2015 /PRNewswire/ — Majid Al Futtaim, the leading shopping mall, retail and leisure pioneer across the Middle East and North Africa (MENA) and Authentic Brands Group, LLC. (ABG) today announced a long term strategic partnership to accelerate global luxury lifestyle brand, Juicy Couture in the Middle East. Majid Al Futtaim  Fashion, the fashion retailing arm of Majid Al Futtaim is now the master retail and wholesale distributor for the brand in the Middle East.

 

“We are committed to growing Juicy Couture in key global markets and the Middle East is a major component of that growth,” said Jamie Salter, Chairman and Chief Executive Officer of ABG. “We have aligned with Majid Al Futtaim Fashion, the wholesale and distribution leader in the MENA territory.”

“Juicy Couture is one of Majid Al Futtaim Fashion’s most established and best-performing labels in our portfolio, having created a thriving business for the lifestyle brand in the region,” said Rajiv Suri, CEO at Majid Al Futtaim Fashion. “Taking on the position of master distributor for Juicy Couture in the region, demonstrates our leadership and expertise in fashion retailing. We look forward to working with ABG to significantly grow Juicy Couture’s presence in the MENA market over the coming years.”   

As the appointed exclusive distributor for the region, Majid Al Futtaim  Fashion will create a harmonised brand presence across its point-of-sale networks including boutiques, shop-in-shops and wholesalers. The Middle Eastern consumer will benefit from access to Juicy Couture’s unique, Los Angeles inspired collections, having a greater selection of apparel to choose from and consistency in pricing across all locations.

Majid Al Futtaim Fashion is focused on the brand’s expansion strategy by opening new Juicy Couture stores with a recent opening in Yas Mall, Abu Dhabi. This month Juicy Couture debuts in Qatar in Lagoona Mall, Doha and is slated to open a number of stores in Saudi Arabia in 2015.

The next phase of growth in the Middle East will center on creating an integrated distribution network beyond shopping malls. Building on the success of Juicy Couture’s Black Label Collection, a major push in eCommerce, with both omni-channel and wholesale online accounts, will significantly extend the brand’s reach across the territory.

Majid Al Futtaim – Fashion first introduced Juicy Couture to the Middle East in 2007 with a boutique in Dubai. Today, the luxury lifestyle brand is its best performing label with 19 freestanding stores in UAE, KSA, Lebanon, Kuwait and Bahrain and plans to open thirty new stores across the region by 2019.

About Majid Al Futtaim Fashion:

Majid Al Futtaim Fashion is the fashion retailing arm of Majid Al Futtaim. It currently works with a number of leading fashion brands throughout the GCC & Levant region including Abercrombie & Fitch Co., Hollister, Juicy Couture, HOSS Intropia, Halston Heritage and Jane Norman. Majid Al Futtaim Fashion recently announced strategic franchises with leading brands AllSaints and Maisons du Monde.

About Majid Al Futtaim

Founded in 1992, Majid Al Futtaim is the leading shopping mall, retail and leisure pioneer across the Middle East and North Africa (MENA).

A remarkable business success story, Majid Al Futtaim started from one man’s vision to transform the face of shopping, entertainment and leisure, and to create great moments for everyone, every day. It has since grown into one of the United Arab Emirates’ most respected and successful businesses spanning 12 international markets, employing over 26,000 people, and achieving the highest credit rating (BBB) among privately-held corporates in the Middle East.

Majid Al Futtaim owns and operates 17 shopping malls, 11 hotels and three mixed-use communities in MENA, with further developments underway in the region. This includes Mall of the Emirates, City Centre malls, and also 4 community malls which are in joint venture with the Government of Sharjah. It holds exclusive rights to the Carrefour franchise in 19 markets across MENA and Central Asia, operating a portfolio of over 50 hypermarkets and over 60 supermarkets in 14 countries. 

Majid Al Futtaim operates 109 VOX Cinemas screens and 17 Magic Planets across the region in addition to iconic leisure and entertainment facilities such as Ski Dubai and iFly Dubai among others. Majid Al Futtaim is parent to the consumer finance company issuing ‘Najm’ credit cards, a fashion retail business representing international brands such as Abercrombie & Fitch, Juicy Couture and Halston Heritage and a healthcare business. In addition, it also has a joint venture operation with Dalkia and has recently expanded into food & beverage in partnership with Gourmet Gulf.

About Juicy Couture:  
Juicy Couture is a glamorous, irreverent, and fun lifestyle brand for the decidedly fashionable, bringing LA style and attitude to girls all over the world. Embracing its Los Angeles heritage, Juicy discovers the couture in the every day, and delivers an element of surprise in all of its designs. The global phenomenon is identified as a casual luxury brand, offering apparel in the categories of women, girls and baby, handbags, shoes, intimates, swimwear, fragrance, accessories and jewelry. Juicy Couture is available in approximately 200 Juicy Couture stores, Juicy Couture outlet stores and select department stores approximately 60 countries throughout North America, Europe, Asia, Latin America, Africa and the Middle East. For updates and more information, please visit visit JuicyCouture.com. Follow Juicy Couture on Facebook, Twitter, Tumblr, Pinterest, Instagram and blog, The Juicy.
Juicy Couture is a trademark owned by ABG Juicy Couture, LLC.

About Authentic Brands Group, LLC

Authentic Brands Group, in partnership with Leonard Green & Partners, is an intellectual property corporation with a mandate to acquire, manage and build long-term value in prominent consumer brands. Headquartered in New York City, ABG’s mission is to further enhance brand equity through partnering with best-in-class licensees and direct-to-retail partnerships. ABG brands include Marilyn Monroe®, Mini Marilyn™, Muhammad Ali®, Elvis Presley®, Juicy Couture®, Judith Leiber®, Adrienne Vittadini®, Taryn Rose®, Hickey Freeman®, Hart Schaffner Marx®, Palm Beach®, Misook®, Prince®, Spyder®, Airwalk®, Above The Rim®, Vision Street Wear®, Hind®, Ektelon®, Viking®, Bobby Jones®, TapouT®, Sportcraft®. www.abg-nyc.com.

Media Contacts:

Majid Al Futtaim Fashion PR Agency:
Weber Shandwick
Lucy Perrott         
+971557761486
lperrott@webershandwick.com

Rebecca Jackson
+971557493602

Juicy Couture & ABG:
Haley Steinberg
+16466127439
hsteinberg@abg-nyc.com

Logo – http://photos.prnasia.com/prnh/20150123/8521500453LOGO-a
Logo – http://photos.prnasia.com/prnh/20150123/8521500453LOGO-b

KT and Ubitus Join Hands to Accelerate Cloud Gaming Service on IPTVs in Korea

TAIPEI and SEOUL, South Korea, Jan. 7, 2015 /PRNewswire/ — Ubitus Inc., the worldwide cloud gaming leader, and KT Corporation, the largest telecommunication service provider in South Korean, are excited to announce their partnership in cloud gaming service today.

KT Corporation has launched its gaming service “Wizgame” on IPTV Set-top-box and plans to strengthen the service by extending game line up in this year. With the collaboration with Ubitus, more blockbuster game titles from leading game companies worldwide will be expected to land on KT’s “Wizgame” going forward. Users will be able to download the updated app in KT’s Appstore from April.

Moreover, KT’s HTML5 Set-top-box devices (three to five models) will be upgraded to support cloud gaming by April, which would enable 60%~70% of existing KT IPTV 5 million subscribers to access cloud gaming service. Ubitus is also aimed to support as many set-top-box devices as possible to expand the device coverage. By the end of this year, 80%~90% subscribers would be able to enjoy cloud gaming service.

Powered by Ubitus’ GameCloud ® solution, KT’s set-top boxes can deliver instant console gaming experiences on demand without the need for users to equip with expensive high-end computers or game consoles as prerequisites. Users will be amazed by the incredible console-level gaming experience, similar to that of PS4 or Xbox, streaming down via their home broadband connections from the cloud.

“Ubitus is thrilled to collaborate with KT and bring ‘Wizgame’ cloud gaming service to the next level in Korea market. We are devoted to enhance customers’ satisfaction by bringing more attractive services and contents to users,” said Wesley Kuo, CEO of Ubitus.

About Ubitus Inc.

Ubitus Inc. has the world’s leading game virtualization technology and cloud-streaming platform. It strives to provide a more pervasive gaming user experience using top-notch technology, allowing players to play the best games at any time and any place as long as they are connected to the internet. The services are compatible across devices, platforms, and networks. It doesn’t matter if the player is using a smart phone, tablet, PC, or smart TV.

As one of the leaders in cloud gaming technology and game streaming services, Ubitus has entered into long-term partnerships with top-notch international game developers, becoming the agent for many classic gaming masterpieces. It has penetrated the Japanese, Korean, US, Hong Kong, and mainland Chinese market. It has liaised with leading telecom service providers, online service providers, and game makers everywhere to provide services to local gamers.

The company was established in 2007, headquartered in Taipei, Taiwan. It currently has 140 employees, and has offices in the US, Japan, South Korea, and Mainland China. Since it was established, it has been generating record-breaking achievements in the global cloud gaming market and received widespread industry recognition in the respective countries and regions.

For more information, please visit the website of Ubitus: http://www.ubitus.net.

Media Contact

Ubitus Inc.
TEL: +886-2-2717-6123
contact@ubitus.net

About KT Corporation

KT Corporation is a South Korean integrated wired/wireless telecommunication service provider. KT focuses on information and communications business, and it has the largest portion of the South Korean local telephone and high-speed Internet market. Originally founded in 1981 as a public corporation, KT actively led Korea’s transition to the information era and played a key role in promoting the growth of Korea into a globally recognized IT superpower.

Logo – http://www.prnasia.com/sa/2013/05/14/20130514115411922696-l.jpg

Janssen Announces Collaboration with Gilead to Develop PREZISTA(R)-based Single-tablet Regimen for the Treatment of People Living with HIV

CORK, Ireland, Dec. 29, 2014 /PRNewswire/ —

— Two Companies to also Collaborate on the Further Development of Complera®, Marketed as Eviplera® in the European Union —

Janssen R&D Ireland (Janssen) announced today an amendment to its existing agreement with Gilead Sciences, Inc. (Gilead), initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV. This new STR contains a combination of darunavir (PREZISTA®), cobicistat (TYBOST®), emtricitabine and tenofovir alafenamide (TAF). A number of Phase 1 and 2 studies of the new STR have been completed. Under this amended agreement, Janssen will conduct all further clinical development of the regimen and, subject to regulatory approval, will be responsible for all manufacturing, registration, distribution and commercialization of the product worldwide.

Logo: http://photos.prnewswire.com/prnh/20140324/NY88746LOGO

If successfully developed and approved by regulatory authorities, this treatment would represent the first protease inhibitor-based STR and thereby continue Janssen’s commitment to providing its HIV products in more simplified dosing presentations.

“Janssen has vast experience in developing and making innovative HIV treatments available to patients and we have engaged in several successful collaborations with Gilead. We are proud to be extending our collaboration and leading the development of this darunavir-based single-tablet regimen,” says Paul Stoffels, Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. “Our ultimate goal is to offer new treatment options for people living with HIV. If approved, this STR has the potential to provide additional choice in the form of another one pill, once a day, as a new and simplified regimen.”

In addition to this collaboration, Janssen and Gilead have also expanded a separate agreement initiated in 2009 regarding the approved single-tablet regimen, COMPLERA®, marketed as EVIPLERA® in the European Union (EU) (rilpivirine, tenofovir disoproxil fumarate (TDF) and emtricitabine). This expanded agreement will allow for Gilead’s investigational tenofovir alafenamide (TAF), a novel nucleotide reverse transcriptase inhibitor, to replace TDF within COMPLERA®/ EVIPLERA®. TAF has been shown in clinical trials to have a better renal and bone safety profile than TDF.[1] Gilead will be responsible for the development and commercialization in most countries, while Janssen will lead the commercialization in select markets.

Since the beginning of the HIV epidemic, almost 75 million people have been infected with the HIV virus.[2] It is estimated that 35 million people are currently living with HIV globally, with 2.5 million people becoming newly infected each year.[2],[3],[4]

——— 

PREZISTA® 

Indication 

PREZISTA® (darunavir), coadministered with ritonavir (PREZISTA®/r), and with other antiretroviral agents (ARVs), is indicated for the treatment of human immunodeficiency virus (HIV-1) infection.

This indication is based on analyses of plasma HIV-1 RNA levels and CD4+ cell counts from 2 controlled Phase 3 trials of 48 weeks duration in ARV treatment-naïve and treatment-experienced patients and 2 controlled Phase 2 trials of 96 weeks duration in clinically advanced, treatment-experienced adult patients.

In treatment-experienced adult patients, the following points should be considered when initiating therapy with PREZISTA®/r:

  • Treatment history and, when available, genotypic or phenotypic testing should guide the use of PREZISTA®/r
  • The use of other active agents with PREZISTA®/r is associated with a greater likelihood of treatment response

Important Safety Information 

PREZISTA® (darunavir) is a prescription medicine. It is one treatment option in the class of HIV (human immunodeficiency virus) medicines known as protease inhibitors.

PREZISTA® is always taken with and at the same time as ritonavir (Norvir®), in combination with other HIV medicines for the treatment of HIV infection in adults. PREZISTA® should also be taken with food.

  • The use of other medicines active against HIV in combination with PREZISTA®/ritonavir (Norvir®) may increase your ability to fight HIV. Your healthcare professional will work with you to find the right combination of HIV medicines
  • It is important that you remain under the care of your healthcare professional during treatment with PREZISTA®

PREZISTA® does not cure HIV infection or AIDS and you may continue to experience illnesses associated with HIV-1 infection, including opportunistic infections. You should remain under the care of a doctor when using PREZISTA®. 

Please read Important Safety Information below, and talk to your healthcare professional to learn if PREZISTA® is right for you. 

Important Safety Information 

What is the most important information I should know about PREZISTA®? 

  • PREZISTA® can interact with other medicines and cause serious side effects. See “Who should not take PREZISTA®?”
  • PREZISTA® may cause liver problems. Some people taking PREZISTA®, together with Norvir® (ritonavir), have developed liver problems which may be life-threatening. Your healthcare professional should do blood tests before and during your combination treatment with PREZISTA®. If you have chronic hepatitis B or C infection, your healthcare professional should check your blood tests more often because you have an increased chance of developing liver problems
  • Tell your healthcare professional if you have any of these signs and symptoms of liver problems: dark (tea-colored) urine, yellowing of your skin or whites of your eyes, pale colored stools (bowel movements), nausea, vomiting, pain or tenderness on your right side below your ribs, or loss of appetite
  • PREZISTA® may cause a severe or life-threatening skin reaction or rash. Sometimes these skin reactions and skin rashes can become severe and require treatment in a hospital. You should call your healthcare professional immediately if you develop a rash. However, stop taking PREZISTA® and ritonavir combination treatment and call your healthcare professional immediately if you develop any skin changes with these symptoms: fever, tiredness, muscle or joint pain, blisters or skin lesions, mouth sores or ulcers, red or inflamed eyes, like “pink eye.” Rash occurred more often in patients taking PREZISTA® and raltegravir together than with either drug separately, but was generally mild

Who should not take PREZISTA®? 

  • Do not take PREZISTA® if you are taking the following medicines: alfuzosin (Uroxatral®), dihydroergotamine (D.H.E.45®, Embolex®, Migranal®), ergonovine, ergotamine (Cafergot®, Ergomar®), methylergonovine, cisapride (Propulsid®), pimozide (Orap®), oral midazolam, triazolam (Halcion®), the herbal supplement St. John’s wort (Hypericum perforatum), lovastatin (Mevacor®, Altoprev®, Advicor®), simvastatin (Zocor®, Simcor®, Vytorin®), rifampin (Rifadin®, Rifater®, Rifamate®, Rimactane®), sildenafil (Revatio®) when used to treat pulmonary arterial hypertension, indinavir (Crixivan®), lopinavir/ritonavir (Kaletra®), saquinavir (Invirase®), boceprevir (Victrelis™), or telaprevir (Incivek™)
  • Before taking PREZISTA®, tell your healthcare professional if you are taking sildenafil (Viagra®, Revatio®), vardenafil (Levitra®, Staxyn®), tadalafil (Cialis®, Adcirca®), atorvastatin (Lipitor®), rosuvastatin (Crestor®), pravastatin (Pravachol®), or colchicine (Colcrys®, Col-Probenecid®). Tell your healthcare professional if you are taking estrogen-based contraceptives (birth control). PREZISTA® might reduce the effectiveness of estrogen-based contraceptives. You must take additional precautions for birth control, such as condoms

This is not a complete list of medicines. Be sure to tell your healthcare professional about all the medicines you are taking or plan to take, including prescription and nonprescription medicines, vitamins, and herbal supplements. 

What should I tell my doctor before I take PREZISTA®? 

  • Before taking PREZISTA®, tell your healthcare professional if you have any medical conditions, including liver problems (including hepatitis B or C), allergy to sulfa medicines, diabetes, or hemophilia
  • Tell your healthcare professional if you are pregnant or planning to become pregnant, or are breastfeeding
  • The effects of PREZISTA® on pregnant women or their unborn babies are not known. You and your healthcare professional will need to decide if taking PREZISTA® is right for you
  • Do not breastfeed. It is not known if PREZISTA® can be passed to your baby in your breast milk and whether it could harm your baby. Also, mothers with HIV should not breastfeed because HIV can be passed to your baby in the breast milk

What are the possible side effects of PREZISTA®? 

  • High blood sugar, diabetes or worsening of diabetes, and increased bleeding in people with hemophilia have been reported in patients taking protease inhibitor medicines, including PREZISTA®
  • Changes in body fat have been seen in some patients taking HIV medicines, including PREZISTA®. The cause and long-term health effects of these conditions are not known at this time
  • Changes in your immune system can happen when you start taking HIV medicines. Your immune system may get stronger and begin to fight infections that have been hidden
  • The most common side effects related to taking PREZISTA® include diarrhea, nausea, rash, headache, stomach pain, and vomiting. This is not a complete list of all possible side effects. If you experience these or other side effects, talk to your healthcare professional. Do not stop taking PREZISTA® or any other medicines without first talking to your healthcare professional

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please refer to the ritonavir (Norvir®) Product Information (PI and PPI) for additional information on precautionary measures.

Please see full Product Information for more details: 

http://www.prezista.com/sites/default/files/pdf/us_package_insert.pdf#zoom=100

About Janssen Pharmaceutical Companies of Johnson & Johnson 

The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving some of the most important unmet medical needs of our time in infectious diseases and vaccines, oncology, immunology, neuroscience, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world.  

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 including regarding product development.  The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen R&D Ireland and/or Johnson & Johnson.  Risks and uncertainties include, but are not limited to: challenges inherent in new product development, including obtaining regulatory approvals;  competition, including technological advances, new products and patents attained by competitors; changes to regulations and domestic and foreign health care reforms; and general industry conditions, including trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 29, 2013, including in Exhibit 99 thereto, and the company’s subsequent filings with the Securities and Exchange Commission.  Copies of these filings are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson.  None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertake to update any forward-looking statement as a result of new information or future events or developments.

New Possibilities in the Fight Against Pancreatic Cancer

ZUG, Switzerland, Dec. 19, 2014 /PRNewswire/ — Licence extension in the contract between AmVac and the Helmholtz Centre for the adjuvant Malp-2 offers sustainable potential for patients, attending physicians and for pharmaceutical and medical research.

Milestone thanks to licence extension 

The licence for Malp-2 was successfully extended in November 2014. The adjuvant can now be used for the first time for all preventive and therapeutic applications, for example in cancers, especially pancreatic cancer, opening a new chapter in the success story of Malp-2. Previously, the adjuvant has been combined in the preclinical phase with a variety of vaccines, enabling the dose of the vaccine to be reduced while simultaneously increasing its effectiveness.

A win-win-win situation has now been created: the person vaccinated gets a twofold benefit and the manufacturer saves significantly on costs. And thanks to the exclusive licence agreement now agreed with the Helmholtz Centre for Infection Research in Braunschweig, AmVac will be able to significantly extend the scope of application of Malp-2. The focus here is on the treatment of certain cancers such as pancreatic cancer, where the drug offers promising opportunities. Malp-2 can be used together with other drugs or in isolation.

Study shows that Malp-2 can extend the life of cancer patients 

Back in 2007, a study conducted at the University Hospital Heidelberg showed that Malp-2 can open up new possibilities. The study was primarily designed to demonstrate a safe use of Malp-2 in pancreatic cancer patients and, secondarily, to confirm the initial indications of its effectiveness against cancer. It was successfully shown that Malp-2 can be used safely in people and that it leads to a significant prolongation of survival time. Initial indications point to an efficient activation of the body’s immune system, which is directed against the cancerous tissue. This is a process that is normally actively suppressed by the cancer.

Detailed information on Malp-2 and its applications can be found on the website of Professor Peter Mühlradt at http://malp-research.de/index.html .

The next development step is a clinical phase II study, which will involve the accurate detection of the adjuvant’s effectiveness depending on the dose as well as further clarification of the mode of action of Malp-2 against cancer. Thanks to the licence extension, the potential of AmVac AG should also increase considerably. “With the multitude of options, we can significantly strengthen our pipeline and broaden the range of applications significantly,” highlights Melinda Karpati, CEO of AmVac. Also to be seen as a positive sign is the fact that, under the licence agreement, the Helmholtz Institute will increase the equity interest it has held to date in AmVac.

Persistent tumour 

Adenocarcinoma of the pancreas and its variants is one of the most common malignant tumours. Adenocarcinoma is the name given to malignant tumours formed from glandular tissue. Causing 18,000 to 100,000 new cases a year, it is the third most common cancer of the digestive tract. Pancreatic cancer accounts for about 3 percent of cancers in Germany and is ranked in ninth place for men and in seventh place for women. In Switzerland, around 1,100 people are diagnosed with pancreatic cancer each year, which also corresponds to about 3 percent of all cancers. Particularly striking here is the high mortality rate: in Europe this cancer is ranked between fourth and seventh place depending on the country.

What  is Malp-2? 

Malp-2 is what is known as a prospective drug. It is a small molecule consisting of a lipid part and a peptide part. Malp-2 activity was discovered by accident in cell cultures that were contaminated with mycoplasmas. Mycoplasmas are very small bacteria that were once believed to be viruses, because they pass through filters that retain bacteria.

Malp-2 works like this: we have an ‘innate’ and an ‘adaptive’ immune system with a memory for diseases that have been successfully overcome, for example. The innate immune system consists among other things of phagocytes, including macrophages. The adaptive immune system is composed of other white blood cells, the lymphocytes. Macrophages and dendritic cells (which monitor the immune system) work together through messengers and cell contacts with lymphocytes. In mice, Malp-2 has increased the production of antibodies, and it has also accelerated the healing of chronic wounds in obese mice. These animals develop diabetes and it is as difficult for their wounds to heal as it is for their human counterparts. Furthermore, Malp-2 has been injected during surgery on humans into tumours that were inoperable. It has proved possible to extend the survival of patients with pancreatic cancer in this way.

About AmVac 

AmVac is a biopharmaceutical company that develops and markets innovative vaccines. Its headquarters are in Zug, Switzerland, and it has research laboratories in Germany and Italy and a production facility in Hungary. This international company can thus rely on the expertise of European specialists who are leaders in their field. 

The company’s portfolio currently includes five vaccine candidates and three platform technologies – Gynevac, Sendai and Malp. They are licensed by a Hungarian partner and leading German institutes of the Helmholtz- und Max-Planck-Gesellschaft. 

AmVac’s leading product is Gynevac, which has already been approved for selected indications and regions and is currently being widely developed for the treatment of especially frequent urogenital diseases. Thanks to its unparalleled security profile, it has been possible for the first time to offer an effective and virtually side effect-free treatment or prevention of benign prostate enlargement, inflammation of the prostate, bacterial vaginitis and trichomonas infection. 

Contact
Marie-Christine Kopkow, President of the Board
Tel.: +41-(41)-7253230, e-mail: kopkow@amvac.eu
AmVac AG, Metallstrasse 4, 6300 Zug, Switzerland
http://www.amvac.eu

China Bolsters International Response to Ebola with USD $6 Million Donation

— Government of China Contributes More Funds to Tackle Ebola Outbreak

BEIJING, Dec. 2, 2014 /PRNewswire/ — On behalf of the Chinese Government, the Ministry of Commerce (MOFCOM) signed into agreement a pledge of USD $6 million to the Ebola Response Multi-Partner Trust Fund (MPTF) made to support  the outbreak which has affected 1.3 million people in West Africa and beyond.

China has so far contributed 750 million yuan (USD $123 million) to 13 African countries and international organizations to combat Ebola (including USD $6 million to WFP and USD $2 million to WHO). This new agreement signals a step up in China’s active engagement in tackling the global health challenge. Due to the unprecedented size and scale of the current outbreak, the United Nations highly appreciates China’s timely contribution to the Fund.

The Secretary-General said he is “heartened by the continued generous mobilization of the international community in support of those countries most affected by the Ebola outbreak in West Africa. China has been a leader in providing financial and in-kind commitments to the global Ebola response.” He said he “welcomes China’s donation of a fully staffed 100-bed treatment centre in Liberia and its latest commitment of USD $6 million to the UN Ebola Response Multi-Partner Trust Fund, which is designed to finance critical unfunded priorities in the fight to end Ebola transmission.”

UN Agencies have already been working on the ground in the worst affected areas by providing up-to-date Ebola Response Roadmaps for all Country Offices, purchasing vital food supplies and healthcare and focusing on the two main relief areas of supporting efforts to stop the epidemic and ensuring that countries, communities and individuals can recover quickly and sustainably.

The agreement was signed into effect at the Ministry of Commerce by Mr. Zhang Xiangchen, Assistant Minister of Commerce and Mr. Alain Noudehou, the UN Resident Coordinator and UNDP Resident Representative acting on behalf of the Multi-Partner Trust Fund.

“Over a long time, China and relevant United Nations organizations, including the UNDP, have launched a wealth of effective collaborative initiatives,” Said Mr. Zhang Xiangchen, “we hope that both sides will deepen this relationship and continually enrich this notion of cooperation.”

At the signing ceremony, Mr. Alain Noudehou expressed gratitude for the very generous contribution made by the Government of China to fight the Ebola Outbreak and reiterated the commitment to continue strengthening the excellent cooperation between the UN system and China.

The Walt Disney Company & Shanghai Media Group Expand Strategic Entertainment Alliance in China

Long-standing relationship to be broadened to include television content development, movie co-production, content distribution and marketing cooperation

SHANGHAI, Nov. 21, 2014 /PRNewswire/ — At a meeting in Shanghai this week, The Walt Disney Company in Shanghai and Shanghai Media Group (SMG) announced they would expand their strategic relationship to include television content development, movie co-production, content distribution, and co-operation on marketing. The series of projects represents another significant step by both organizations to develop a vibrant creative content industry and connect with audiences in China and globally.

Disneynature Born in China Landscape

Disneynature Born in China Landscape

 

Disneynature Born in China Panda Family

Disneynature Born in China Panda Family

 

Disneynature Born in China Snow Leopard Family

Disneynature Born in China Snow Leopard Family

“The strength of this deepening relationship with Disney, and the volume and diversity of the initiatives that we are pursuing, helps set the foundation of a multi-faceted strategic alliance with Disney,” said Mr. Li Ruigang, Chairman, Shanghai Media Group.

“The series of projects we are announcing today represents an exciting new phase in our long-term alliance. We believe that they will serve as the cornerstone of actualizing SMG’s vision in applying world-class creative process; contribute towards the success of local content creation for international markets and create new business models across both digital media and traditional spaces. The endeavors will help us to transform the organization and accelerate its path towards digital success,” Mr. Li added.

“Disney is committed to providing high quality entertainment experiences to audiences worldwide,” said Mr. Robert Iger, Chairman and Chief Executive Officer, The Walt Disney Company. “SMG’s spirit of innovaton, diverse platforms, digital destinations and assets provide unparalleled access to that entertainment in China.”

Disney and SMG enjoy a long-standing relationship that would be expanded to include television content development, movie co-production, content distribution and marketing cooperation.

  • Born in China, a new Disneynature film currently in production in China, will showcase to the world the spectacular wildlife and natural beauty of China when it opens at the global box office in 2016.  Disneynature today revealed that the movie includes rare footage of endangered snow leopards. This film is in addition to the previously announced multi-year studio movie script and talent development fund between The Walt Disney Studios and Shanghai Media Group Pictures (SMG Pictures) with the ultimate goal of co-developing Disney-branded movies for US-China co-productions.
  • Disney is in active discussion with Toonmax to produce a kids’ animation series that centers on one of China’s most popular cultural icons. By combining the best talent, creative processes, and cultural insights from both sides, Disney and Toonmax will set out to create a top quality show for kids and families with an ambition for global distribution.
  • In 2013, Disney and BesTV New Media Company Limited (China’s number one IPTV operator and the digital media subsidiary of the Shanghai Media Group) agreed to form, and today are in the final steps of registering, a joint venture company in Shanghai that will expand families’ and kids’ digital choices.
  • SMG and Disney intend to work closely on a number of marketing initiatives, expanding on their prior collaborations in television and film.

“This unique and far reaching cooperation between Disney and SMG is testimony to the strength of our 15-year relationship and commitment to serving audiences with world class family entertainment,” said Mr. Stanley Cheung, Chairman, The Walt Disney Company Greater China.

Images Copyright (C) Disneynature 2014

-End-

About The Walt Disney Company in China

The Walt Disney Company (NYSE:DIS), together with its subsidiaries and affiliates, is a diversified international family entertainment enterprise with five business segments with over 137 000 employees. Our first animation screened in China in the 1930s and today our long association continues with offices in Beijing, Shanghai and Guangzhou with over 3000 employees.  Disney is a Dow 30 Company, had annual revenues of over US$48 billion in its most recent fiscal year, and a market capitalization of US$155billion as of 19 November 2014.

About SMG

Shanghai Media Group (SMG) is one of the largest media and entertainment company in China. SMG boasts the most valuable and comprehensive business portfolio including radio, TV, newspaper and magazine traditional media outlets, TV program/drama and motion picture productions and distribution, multiplatform video distribution such as IPTV and Internet TV, and online video offerings, digital advertising, online and console gaming, TV shopping and ecommerce , live and performing arts and tourism. By the end of 2013, SMG had RMB 44.6 billion in assets and RMB 21 billion annual income.

In terms of media outlets, SMG currently operates 15 satellite and cable networks, including news, entertainment, sports, finance, documentary, children networks, which are based on free-to-air advertising business model. Among them, the flagship channel Dragon TV is one of the most influential satellite TV channels in China, reaching 1 billion audience members in China and overseas markets, covering Hong Kong, Macao, the United States, and Canada. Meanwhile, SMG has 15 pay TV channels distributed national wide, only based on subscription business model.SMG also owns and operates 12 radio stations, including news, sports, finance, music stations ,and 8 newspapers and magazines. In terms of industrial development, SMG has two public listed companies: BesTV New Media and Oriental Pearl, with the total market value exceeding 70 billion RMB and ranking No1 and No2 in all public listed media and entertainment companies in market capitalization. Also, SMG runs the largest home shopping business in China. It also owns several landmark properties in the city including Oriental Pearl Radio & TV Tower. Looking forward, SMG will stick to its mission of “spreading uplifting power and enriching people’s life” and strive to become China’s most innovative media and entertainment conglomerate with global influence.

About Toonmax

Toonmax is China’s leading company in children’s programming and animation productions. It operates two TV networks including a satellite channel targeted at teenagers and a local cable channel whose core audiences are kids and families. Its businesses also encapsulate animation investment & branded exhibition, children’s arts education, licensing and consumer products. It is a core member of the Shanghai Animation Association, a key national animation production enterprise and cultural export entity.

About BesTV

BesTV New Media Co Ltd (SHA:600637) is an A-share listed new media company controlled by Shanghai Broadcasting TV Station and Shanghai Media Group (SMG). BesTV New Media owns 100 percent equity of BesTV NetTV Technology Development Co., Ltd, Shanghai Media & Entertainment Technology Group and Shanghai Film, Radio & TV Production Co., Ltd. BesTV also controls Funshion Network, and has established a joint venture with Microsoft, Lenovo and ZTE Corporation. All of these have led BesTV to build the largest new media industry cluster in China. The company covers more than 20 provinces/cities in Mainland China and South East Asia with a new media business portfolio including IPTV, internet TV, smart TV, OTT and mobile TV, and established a presence in Asia-Pacific and Africa regions with technologies, equipment and film & television production channel.

About Disneynature

Disneynature was launched in April 2008. Its mission is to bring the world’s top nature filmmakers together to share a wide variety of wildlife stories on the big screen in order to engage, inspire and educate theatrical audiences everywhere. Walt Disney was a pioneer in wildlife filmmaking, producing 13 True-Life Adventure motion pictures between 1948 and 1960, which earned eight Academy Awards®. The first five Disneynature films, “Earth,” “Oceans,” “African Cats”, “Chimpanzee,” and “Bears, “are five of the top six highest overall grossing feature-length nature films to date, with “Chimpanzee” garnering a record-breaking opening weekend for the genre. Disneynature’s commitment to conservation is a key pillar of the label and the films empower the audience to help make a difference. Through donations tied to opening-week attendance for all five films, Disneynature, through the Disney Worldwide Conservation Fund, has planted three million trees in Brazil’s Atlantic Forest, established 40,000 acres of marine protected area in The Bahamas, protected 65,000 acres of savanna in Kenya, protected nearly 130,000 acres of wild chimpanzee habitat, cared for chimpanzees, educated 60,000 school children about chimpanzee conservation and funded research and restoration grants in US National Parks supporting conservation projects across 2.9 million acres of parkland and protecting endangered species. For more information about Disneynature, like us on Facebook: http://facebook.com/Disneynature and follow us on Twitter: http://twitter.com/Disneynature

Photo – http://photos.prnasia.com/prnh/20141121/0861408770-a
Photo – http://photos.prnasia.com/prnh/20141121/0861408770-b
Photo – http://photos.prnasia.com/prnh/20141121/0861408770-c

National Football League China Enlists Epsilon to Drive Engagement with Fans

SHANGHAI, Nov. 19, 2014 /PRNewswire/ — Epsilon, an Alliance Data (NYSE: ADS) company, has signed a new multi-year agreement with National Football League China (NFL China), a subsidiary of the professional American football league, the NFL. Epsilon will provide a robust platform for NFL China to manage its audience subscriptions and communications, which enables a holistic view and more insights on its member base.

Since establishing an office in China in October 2007, the NFL has been devoted to promoting the game of football in China. This season, NFL games air across over 20 regional TV channels, reaching more than 96 million unique viewers, and 5 nationwide online broadcasters, allowing games to be streamed live and on-demand. The official NFL China website (http://www.nflchina.com) offers localized content, such as game news, broadcast schedules, and the latest information on NFL teams and players. In addition, NFL China offers a number of on-ground events for beginners and football enthusiasts of all ages, including the “NFL HOME FIELD,” a 10-week initiative which provided a home base for football in Beijing, Shanghai and Guangzhou offering visitors a chance to experience football through on-field clinics, family-friendly interactive games and live tackle football games featuring local teams; and the “NFL On Tour”, a large scale truck tour that brought a mobile audio/visual NFL experience to 9 cities across the Mainland.

Under the terms of the multiyear agreement, Epsilon will provide a suite of services including design and build of a single customer view marketing database, full service email marketing including campaign management, delivery management, strategy and analytics.

“We are proud to expand our partnership with Epsilon and look forward to utilizing Epsilon’s insights to deepen fan engagement and further connect with our NFL fans in China,” said Richard Young, Managing Director of NFL China. 

“NFL China is an energetic and innovative player in the local sports scene. In addition to bringing the fun game to the Chinese people, its commitment to enhancing the NFL experience aligns closely with Epsilon’s strength, which is to create connections with people by leveraging data, focus on understanding consumer behavior and drive results,” said Michael Kustreba, Managing Director of Epsilon, Asia Pacific. “I am confident that Epsilon will deliver tremendous value with our leading digital capabilities and extensive experience in serving our clients in China.”

About Epsilon

Epsilon is the global leader in creating connections between people and brands. An all-encompassing global marketing company, we harness the power of rich data, groundbreaking technologies, engaging creative and transformative ideas to get the results our clients require. Epsilon is recognized by Ad Age as the #1 World CRM/Direct Marketing Network and #1 U.S. Agency from All Disciplines. We employ over 5,000 associates in 60 offices worldwide. Epsilon is an Alliance Data company.

Epsilon International is an operating unit of Epsilon, with local offices in Australia, mainland China, Hong Kong, India, Japan, Singapore, the U.K., France, Germany and Ireland. For more information, visit epsilon.com, follow us on Twitter @EpsilonAPAC or email to apac-info@epsilon.com.

About NFL & NFL China

Founded in 1920, the National Football League (NFL) has been called “one of America’s best-run businesses” and is admired for its structure, core values and innovative policies that promote athletic competition at the highest level. With 32 teams located across the United States, the NFL is the #1 sports league in America, outranking the NBA (basketball), MLB (baseball) and NHL (hockey) combined as the people’s favorite. The NFL’s championship game, the Super Bowl, is the most-watched program in US TV history and has also become a popular international sports event broadcast in more than 200 countries and territories and in over 30 languages.

NFL China, the league’s fifth international office, was established in Beijing in October 2007, demonstrating the NFL’s long-term commitment to China and is a significant milestone in the NFL’s continuing effort to promote its game worldwide. In China, the NFL aims to develop its fan base, increasing fan avidity and passion for the game through strategic cooperation with national and regional media partners, and focused marketing efforts around flag football development and experiential fan events.

About Alliance Data

Alliance Data® (NYSE: ADS) and its combined businesses is North America’s largest and most comprehensive provider of transaction-based, data-driven marketing and loyalty solutions serving large, consumer-based industries. The Company creates and deploys customized solutions, enhancing the critical customer marketing experience; the result is measurably changing consumer behavior while driving business growth and profitability for some of today’s most recognizable brands. Alliance Data helps its clients create and increase customer loyalty through solutions that engage millions of customers each day across multiple touch points using traditional, digital, mobile and other emerging technologies. Headquartered in Dallas, Alliance Data and its three businesses employ approximately 11,000 associates at more than 70 locations worldwide.

Alliance Data consists of three businesses: Alliance Data Retail Services, a leading provider of marketing-driven credit solutions; Epsilon®, a leading provider of multichannel, data-driven technologies and marketing services; and LoyaltyOne®, which owns and operates the AIR MILES® Reward Program, Canada’s premier coalition loyalty program. For more information about the company, visit our web site, www.alliancedata.com, or follow us on Twitter via @AllianceData.

CONTACT: Epsilon, Rickie Hobbie, +852-3589-0717, rhobbie@epsilon.com

Alibaba and Ubitus Join Hands to Unveil a New Era of Cloud Gaming in China

TAIPEI and HANGZHOU, China, Nov. 14, 2014 /PRNewswire/ — Ubitus Inc., the worldwide cloud gaming technology leader, announced today its partnership with Alibaba’s Digital Entertainment Business Group to launch the cloud gaming service in China. With several cloud gaming products, such as T-mall set –top- boxes (Premium and 1S version) and Haier Connected TVs, users can enjoy new gaming experience to the next level. 

New T-Mall Set-Top-Box - Premium Version
New T-Mall Set-Top-Box – Premium Version

 

Haier Connected TV built-in Cloud Gaming Service

Haier Connected TV built-in Cloud Gaming Service

 

【Note】: Alibaba launched several cloud gaming products, such as T-mall set –top- boxes (premium, 1S version) and Haier connected TVs. Users can enjoy new gaming experience to the next level.

On July 16th, Alibaba Group’s Digital Entertainment Business Group unveiled its “Home Entertainment platform,” in joining hands with partners among leading players in gaming and digital entertainment industries. The new platform will offer online gaming, music and video streaming as well as online education services through Alibaba’s new T-mall set-top boxes based on its cloud computing capabilities. Alibaba’s ambition is to provide an evolutionary, all-around digital home entertainment experience to center on consumers’ “Living Rooms.”  

Among all services introduced, “Cloud Gaming” unquestionably collected the major spotlights for headlines. Powered by Ubitus’ GameCloud ® technologies, Alibaba’s next-generation T-mall set-top boxes and connected TVs can deliver instant console gaming experiences on demand without the need for users to equip with expensive high-end computers or game consoles as prerequisites. Users will be amazed by the incredible console-level gaming experience, similar to that of PS4 or Xbox, streaming down via their home broadband connections from the cloud. More blockbuster game titles from leading game companies worldwide will be expected to land on Alibaba’s cloud gaming platform going forward.

“Ubitus is both honored and proud to be selected by Alibaba to peer up in the launch of its transformational cloud gaming service (platform) with our industry-leading technologies”, said Wesley Kuo, CEO of Ubitus. “We believe that this revolutionized service would bring wowing experience to the gamers playing on Alibaba’s new “living room” devices. People will be amazed by how effortless it is to enjoy on-demand console games without any complicated download or installation process.”

“We are devoted to provide families with great game titles, great movies, great education contents and great services,” said  Mr. Liu Chunning, President of the Digital Entertainment Business Group under the Alibaba Group.  “The joint effort between Alibaba and Ubitus to launch cloud-gaming will bring new digital entertainment experience for home users, enrich families with more entertainment options at home, and rejuvenate the warm atmosphere for every living room in every household, as our purpose of existence has always been for the families and our ambitions are to redefine them.”

T-mall Set-top-box (premium version) : http://goo.gl/NX6RPzT-mall
Set-top-box (1S version) : http://goo.gl/pJbi6E  
Haire Connected TV (40″): http://goo.gl/9cwnuK 
Haire Connected TV (48″): http://goo.gl/ZOdmuJ 
Haire Connected TV (60″): http://goo.gl/XsDzPH 

About Ubitus Inc.】

Ubitus Inc. has the world’s leading game virtualization technology and cloud-streaming platform. It strives to provide a more pervasive gaming user experience using top-notch technology, allowing players to play the best games at any time and any place as long as they are connected to the internet. The services are compatible across devices, platforms, and networks. It doesn’t matter if the player is using a smart phone, tablet, PC, or smart TV.

As one of the leaders in cloud gaming technology and game streaming services, Ubitus has entered into long-term partnerships with top-notch international game developers, becoming the agent for many classic gaming masterpieces. It has penetrated the Japanese, Korean, US, Hong Kong, and Chinese market. It has liaised with leading telecom service providers, online service providers, and game makers everywhere to provide services to local gamers.

The company was established in 2007, headquartered in Taipei, Taiwan. It currently has more than 140 employees, and has offices in the US, Japan, South Korea, and Mainland China. Since it was established, it has been generating record-breaking achievements in the global cloud gaming market and received widespread industry recognition in the respective countries.

For more information, please visit the website of Ubitus. www.ubitus.net

Media Contact
Ubitus Inc.
TEL: +886-2-2717-6123
contact@ubitus.net

Photo – http://photos.prnasia.com/prnh/20141111/8521406716-a
Photo – http://photos.prnasia.com/prnh/20141111/8521406716-b
Logo – http://www.prnasia.com/sa/2013/05/14/20130514115411922696-l.jpg

DKSH Starts Strategic Partnership with BASF in Asia

DKSH, the leading Market Expansion Services provider and BTC Chemical Distribution, a subsidiary of BASF, will start a strategic collaboration for colorants in the personal care and household industries in 14 Asian countries.

BASEL, Switzerland, Nov. 3, 2014 /PRNewswire/ — DKSH’s Business Unit Performance Materials, a leading specialty chemicals distributor, has been appointed to provide Market Expansion Services for BASF’s product range of home and personal care colorants in mainland China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, ‎Myanmar, Philippines, Sri Lanka, Singapore, Thailand, Taiwan and Vietnam.

BASF offers one of the most comprehensive line of colorants for the home and personal care industry. The cooperation includes the product lines Puricolor and Iragon. DKSH Business Unit Performance Materials has been chosen as the exclusive Market Expansion Services partner due to its comprehensive Pan-Asian coverage, through specialized teams in each countries and its broad range of services including eight innovation centers and six regulatory affairs centers.

“We are delighted that BASF has chosen DKSH as their Market Expansion Services partner across South East Asia. We have a strong customer base that has been established over almost 150 years of doing business in Asia. We are convinced that our local business partners will be excited about the opportunity to have access to BASF’s products,” commented Cesar Saez, Vice President, Business Line Personal Care Industry, DKSH Performance Materials.

About BASF

At BASF, we create chemistry  and have been doing so for 150 years. Our portfolio ranges from chemicals, plastics, performance products and crop protection products to oil and gas. As the world’s leading chemical company, we combine economic success with environmental protection and social responsibility. Through science and innovation, we enable our customers in nearly every industry to meet the current and future needs of society. Our products and solutions contribute to conserving resources, ensuring nutrition and improving quality of life. We have summed up this contribution in our corporate purpose: We create chemistry for a sustainable future. BASF had sales of about EUR 74 billion in 2013 and over 112,000 employees as of the end of the year. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA) and Zurich (AN). Further information on BASF is available on the Internet at www.basf.com .

About DKSH

DKSH is the leading Market Expansion Services provider with a focus on Asia. As the term “Market Expansion Services” suggests, DKSH helps other companies and brands to grow their business in new or existing markets.

Publicly listed on the SIX Swiss Exchange since March 2012, DKSH is a global company headquartered in Zurich. With 735 business locations in 35 countries  710 of them in Asia  and 27,200 specialized staff, DKSH generated net sales of CHF 9.6 billion in 2013.

DKSH Business Unit Performance Materials is a leading specialty chemicals distributor and provider of Market Expansion Services for performance materials, covering Europe, North America, and the whole of Asia. The Business Unit sources, develops, markets, and distributes a wide range of specialty chemicals and ingredients for pharmaceutical, personal care, food & beverage, as well as various industrial applications. In addition, it creates innovative and cutting-edge concepts and applications in 27 innovation centers located worldwide. With 90 business locations in 26 countries and around 1,120 specialized staff, Business Unit Performance Materials generated net sales of CHF 770 million in 2013.